Multicenter evaluation of the analytical and clinical performance of the Elecsys ® S100 immunoassay in patients with malignant melanoma
-
Bettina Alber
Abstract
The aim of this multicenter study was to evaluate the technical and clinical performance of the Elecsys ® S100 electrochemiluminescence immunoassay and to assess its utility as a tumor marker in patients with malignant melanoma. Imprecision studies yielded within-run coefficients of variation (CVs) of 0.7–2.0% and between-day CVs of 1.0–6.4%. Serum samples that were distributed to 11 participating laboratories for a comparability analysis resulted in excellent recoveries of 93–105% related to the median for all laboratories. The functional sensitivity of the assay was determined to be below 0.02μg/L. The lot-to-lot reproducibility of Elecsys ® S100 was tested by analyzing 110 sera with three different reagent lots on an E2010 analyzer. This lot-to-lot comparison showed excellent correlation, with a coefficient of 0.99. A 95th percentile cut-off value of 0.10μg/L was calculated from values measured in 206 healthy individuals. Using this cut-off value, sensitivity of 41% was found, with positive and negative predictive values of 0.50 and 0.91, respectively. Method comparison with the Sangtec ® 100 luminescence immunoassay, run on two different analyzers, showed correlation with coefficients ranging from 0.76 to 0.95. A comparison of S100 values obtained with both tests showed identical patterns in 68 serial samples from 15 patients with malignant melanoma during follow-up. These findings indicate that serial measurements with the Elecsys ® S100 assay are useful for the follow-up and monitoring of therapy in patients with malignant melanoma.
References
1 Glass AG, Hoover RN. The emerging epidemic of melanoma and squamous cell carcinoma. Br J Cancer 1998; 78: 40–5. Search in Google Scholar
2 Rivers JK. Melanoma. Lancet 1996; 347: 803–6. 10.1016/S0140-6736(96)90873-9Search in Google Scholar
3 Gaynor R, Irie R, Morton D, Herschman HR. S100 protein is present in cultured human malignant melanomas. Nature 1980; 286: 400–1. 10.1038/286400a0Search in Google Scholar
4 Cochran AJ, Wen DR, Herschman HR. Detection of S-100 protein as an aid to the identification of melanocytic tumours. Int J Cancer 1982; 30: 295–7. 10.1002/ijc.2910300307Search in Google Scholar
5 Schäfer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 1996; 21: 134–40. 10.1016/S0968-0004(96)80167-8Search in Google Scholar
6 Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull 1995; 4: 417–29. 10.1016/0361-9230(95)00040-2Search in Google Scholar
7 Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Technique 2003; 60: 540–51. 10.1002/jemt.10296Search in Google Scholar
8 Guo HB, Stoffel-Wagner B, Bierwirth T, Metzger J, Klingmüller D. Clinical significance of Serum S100 in metastatic malignant melanoma. Eur J Cancer 1995; 31A: 924–8. 10.1016/0959-8049(95)00087-9Search in Google Scholar
9 Kaskel P, Berking C, Sander S, Volkenandt M, Peter RU, Krähn G. S-100 protein in peripheral blood: a marker for melanoma metastases. J Am Acad Dermatol 1999; 41: 962–9. 10.1016/S0190-9622(99)70254-9Search in Google Scholar
10 Mohammed MQ, Abraha HD Sherwood RA, MacRae K, Retsas S. Serum S100β protein as a marker of disease activity in patients with malignant melanoma. Med Oncol 2001; 18: 109–20. 10.1385/MO:18:2:109Search in Google Scholar
11 Krähn G, Kaskel P, Sander S, Pereira Y, Waizenhöfer J, Wortmann S, et al. S100β is a more reliable tumor marker in peripheral blood with newly occurred melanoma metastases compared with MIA, albumin and lactate dehydrogenase. Cancer Res 2001; 21: 1311–6. Search in Google Scholar
12 von Shoultz E, Hansson LO, Djureen E, Hansson J, Nilsson B, Stigbrand T, et al. Prognostic value of serum analysis S-100 protein in malignant melanoma. Melanoma Res 1996; 6: 133–7. 10.1097/00008390-199604000-00008Search in Google Scholar
13 Abraha HD, Fuller LC, Vivier AW, Higgins EM, Sherwood RA. Serum-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol 1997; 46: 381–5. 10.1111/j.1365-2133.1997.tb03742.xSearch in Google Scholar
14 Bablok W, Passing H, Bender R, Schneider B. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry. J Clin Chem Clin Biochem 1988; 26: 783–90. Search in Google Scholar
15 Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307–10. Search in Google Scholar
16 Schlagenhauff B, Schittek B, Ellwanger U, Stroebel W, Blum A, Rassner G, et al. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence? Melanoma Res 2000; 10: 451–9. 10.1097/00008390-200010000-00007Search in Google Scholar PubMed
17 Jury CS, McAllister EJ, MacKie RM. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 2000; 143: 269–74. 10.1046/j.1365-2133.2000.03650.xSearch in Google Scholar PubMed
18 Schultz ES, Diepgen TL, von den Driesch P. Clinical and prognostic relevance of serum S-100β protein in malignant melanoma. Br J Dermatol 1998; 138: 426–30. 10.1046/j.1365-2133.1998.02119.xSearch in Google Scholar PubMed
19 Persson L, Hardemark HG, Gustafsson J, Rundstrom G, Mendel-Hartvig I, Escher T, et al. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 1987; 18: 911–8. 10.1161/01.STR.18.5.911Search in Google Scholar
20 Otto M, Stein H, Szudra A, Zerr I, Bodemer M, Gefeller O, et al. S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol 1997; 244: 566–70. 10.1007/s004150050145Search in Google Scholar PubMed
21 Molina R, Navarro J, Filella X, Castel T, Ballesta AM. S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumor Biol 2002; 23: 39–44. 10.1159/000048687Search in Google Scholar PubMed
© by Walter de Gruyter Berlin New York
Articles in the same Issue
- Second Santorini Conference “From Human Genetic Variations to Prediction of Risks and Responses to Drugs and to the Environment”
- Expressed genome molecular signatures of heart failure
- Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice
- Alcohol and gene interactions
- β-Carotene stimulates chemotaxis of human endothelial progenitor cells
- Effect of interferon-γ, interleukin-10, lipopolysaccharide and tumor necrosis factor-α on chitotriosidase synthesis in human macrophages
- Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients
- Apolipoprotein E haplotyping by denaturing high-performance liquid chromatography
- Both core and terminal glycosylation alter epitope expression in thyrotropin and introduce discordances in hormone measurements
- Do we measure bilirubin correctly anno 2005?
- Differences in mortality on the basis of laboratory parameters in an unselected population at the Emergency Department
- An Italian program of external quality control for quantitative assays based on real-time PCR with Taq-Man™ probes
- A reference material for traceability of aspartate aminotransferase (AST) results
- Harmonization of the Bayer ADVIA Centaur and Abbott AxSYM automated B-type natriuretic peptide assay in patients on hemodialysis
- Multicenter evaluation of the analytical and clinical performance of the Elecsys ® S100 immunoassay in patients with malignant melanoma
- Guidelines for sampling, measuring and reporting ionized magnesium in undiluted serum, plasma or blood: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC): IFCC Scientific Division, Committee on Point of Care Testing
- Evaluation of the Quantase™ neonatal immunoreactive trypsinogen (IRT) screening assay for cystic fibrosis
Articles in the same Issue
- Second Santorini Conference “From Human Genetic Variations to Prediction of Risks and Responses to Drugs and to the Environment”
- Expressed genome molecular signatures of heart failure
- Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice
- Alcohol and gene interactions
- β-Carotene stimulates chemotaxis of human endothelial progenitor cells
- Effect of interferon-γ, interleukin-10, lipopolysaccharide and tumor necrosis factor-α on chitotriosidase synthesis in human macrophages
- Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients
- Apolipoprotein E haplotyping by denaturing high-performance liquid chromatography
- Both core and terminal glycosylation alter epitope expression in thyrotropin and introduce discordances in hormone measurements
- Do we measure bilirubin correctly anno 2005?
- Differences in mortality on the basis of laboratory parameters in an unselected population at the Emergency Department
- An Italian program of external quality control for quantitative assays based on real-time PCR with Taq-Man™ probes
- A reference material for traceability of aspartate aminotransferase (AST) results
- Harmonization of the Bayer ADVIA Centaur and Abbott AxSYM automated B-type natriuretic peptide assay in patients on hemodialysis
- Multicenter evaluation of the analytical and clinical performance of the Elecsys ® S100 immunoassay in patients with malignant melanoma
- Guidelines for sampling, measuring and reporting ionized magnesium in undiluted serum, plasma or blood: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC): IFCC Scientific Division, Committee on Point of Care Testing
- Evaluation of the Quantase™ neonatal immunoreactive trypsinogen (IRT) screening assay for cystic fibrosis
